Carbonic anhydrases: Novel therapeutic applications for inhibitors and activators

Nature Reviews Drug Discovery

Volumn 7, Issue 2, 2008, Pages 168-181

  Supuran, Claudiu T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ANTIGLAUCOMA AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIOBESITY AGENT; BRINZOLAMIDE; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE ACTIVATOR; CARBONATE DEHYDRATASE INHIBITOR; CELECOXIB; CHLOROTHIAZIDE; CHLORTALIDONE; DICLOFENAMIDE; DIURETIC AGENT; DORZOLAMIDE; ENZYME ACTIVATOR; ETHOXZOLAMIDE; FUROSEMIDE; INDAPAMIDE; INDISULAM; ISOENZYME; METHAZOLAMIDE; QUINETHAZONE; SACCHARIN; SULPIRIDE; SULTIAME; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALDECOXIB; ZONISAMIDE;

ALZHEIMER DISEASE; BLURRED VISION; BURNING SENSATION; CARCINOGENICITY; CLINICAL TRIAL; DRUG BINDING; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; EDEMA; ENZYME ACTIVATION; ENZYME INHIBITION; EYE DISEASE; FATTY ACID SYNTHESIS; GLAUCOMA; GLUCONEOGENESIS; HUMAN; LIPOGENESIS; NEOPLASM; NONHUMAN; OBESITY; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; UREA CYCLE; WEIGHT REDUCTION;

ANIMALS; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; DRUG DESIGN; HUMANS; ISOENZYMES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 38849143765     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2467     Document Type: Review

References (121)

1. Scozzafava, A., Mastrolorenzo, A. & Supuran, C. T. Carbonic anhydrase inhibitors and activators and their use in therapy. Expert Opin. Ther. Pat. 16, 1627-1664 (2006).
2. Supuran, C. T., Scozzafava, A. & Conway, J. Carbonic Anbydrase - Its inhibitors and Activators 1-363 (CRC, Boca Raton, 2004).
3. Supuran, C. T., Scozzafava, A. & Casini, A Carbonic anhydrase inhibitors. Med. Res. Rev. 23, 146-189 (2003).
4. Smith, K. S. & Ferry. J. G. Prokaryotic carbonic anhydrases. FEMS Microbiol. Rev. 24, 335-366 (2000).
5. Thiry A. et al. Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol. Sci, 27, 566-573 (2006).
6. Stams, T. & Christianson, D. W. in The Carbonic Anhydroses - New Horizons (eds Chegwidden, W. R., Carter, N. D. & Edwards, Y. H.) 159-174 (Birkhauser, Basel, 2000).
7. Pastorekava, S. et al. Carbonic anhydrases: Current state of the art, therapeutic applications and future prospects. J. Enzyme Inhib. Med. Chem. 19, 199-229 (2004).
8. Nishimori, I. et al. Carbonic anhydrase inhibitors. Cloning. characterization and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg. Med. Chem. 15, 7229-7236 (2007).
9. Vullo, D. et al. Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides, J. Med. Chem. 47, 1272-1279 (2004).
10. Nishimori, I. et al. Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors. J. Med. Chem. 48, 7860-7866 (2005).
11. Nishimori, I. et al. Carbonic anhydrase inhibitors. DNA cloning, characterization and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors. J. Med. Chem. 50, 381-388 (2007).
12. Vullo. D. et al. Carbonic anhydrase inhibitors, Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides. Bioorg. Med. Chem. Lett. 15, 971-976 (2005).
13. Nishimori, I. in Carbonic Anhydrose - Its Inhibitors and Activators (eds Supuran, C. T., Soozzafava, A. & Conway J.) 25-43 (CRC, Boca Raton, 2004).
14. Vullo, D., et al. Carbonic anhydrase inhibitors. Inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg. Med. Chem. Lett. 13. 1005-1009 (2003).
15. Vullo, D. et al. Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides - a new target for the design of antitumor and antiglaucoma drugs? Bioorg. Med. Chem. Lett. 15, 963-969 (2005).
16. Lehtonen, J. et al. Characterization of CA XIII. a novel member of the carbonic anhydrase isozyme family. J. Biol. Chem. 279, 2719-2727 (2004).
17. Nishimori, I. et al. Carbonic anhydrase inhibitors. inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg. Med. Chem. Lett. 15, 3828-3833 (2005).
18. Alterio, V. et al. Carbonic anhydrase inhibitors: X-ray and molecular modeling study for the interaction of a fluorescent antitumor sulfonamide with isozyme II and IX. J. Am. Chem. Soc. 128, 8329-8335 (2006).
19. Köhler, K. et al. Saccharin inhibits carbonic anhydrases: possible explanation for its unpleasant metallic attertaste. Angew. Chem. Int. Ed. Engl. 46, 7697-7699 (2007).
20. Supuran, C. T., Ilies M. A. & Scozzafava, A. Carbonic anhydrase inhibitors. Part 29. Interaction of isozymes I, II and IV with benzolamide-like derivatives. Eur J. Med. Chem. 33, 739-752 (1998).
21. Supuran, C. T, Scozzafava. A., Ilies M. A. & Briganti, F Carbonic anhydrase inhibitors. Synthesis of sulfonamides incorporating 2,4,6-trisubstituted-pyridinium-ethylcarboxamido moieties possessing membrane-impermeability and in vivo selectivity for the membrane-bound (CA IV) virsus the cytosolic (CA I and CA II) isozymes. J. Enz. Inhib. 15, 381-401 (2000).
22. Scozzafava, A., Briganti, F, Ilies, M. A. & Supuran, C. T Carbonic anhydrase inhibitors. Synthesis of membrane-impermeant low molecular weight sulfonamides possessing in vivo selectivity for the membrane-bound versus the cytosolic isozymes. J. Med Chem. 43 292-300 (2000).
23. Winum, J. Y. et al. Carbonic anhydrase inhibitors: Clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue. J. Med. Chem. 49, 7024-7031 (2006).
24. Saczewski, F. et al. Carbonic anhydrase inhibitors. Inhibition of the cytosolic human isozymes I and II, and the transmembrane, tumor-associated isozymes IX and XII with substituted aromatic sulfonamides activatable in hypoxic tumors. Bioorg. Med. Chem. Lett. 16, 4846-4851 (2006).
25. De Simone, G. et al. Carbonic anhydrase inhibitors: hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX. J. Med. Chem. 49, 5544-5551 (2006).
26. Krungkrai, J. et al. Carbonic anhydrase inhibitors. Inhibition of Plasmodium falciparum carbonic anhydrase with aromatic sulfonamides: Towards antimalarials with a novel mechanism of action? Bioorg. Med. Chem. 13, 483-489 (2005).
27. Nishimori, I. et al. Carbonic anhydrase inhibitors. DNA cloning and inhibition studies of the α-carbonic anhydrase from Helicobacter pylori: A new target for developing sulfonamide and sulfamate gastric drugs. J. Med. Chem. 49, 2117-2126 (2006).
28. Nishimori, I. et al. Carbonic anhydrase inhibitors. The β-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors. Bioong. Med. Chem. Lett. 17, 3585-3594 (2007).
29. Suarez Cavarrubias, A. et al. Structure and function of carbonic anhydrases from Mycobacterium tuberculosis. J. Biol. Chem. 280 18782-18789 (2005).
30. 2 sensing with cAMP signaling and virulence. Curr. Biol. 15, 2021-2026 (2005).
31. 2 through the carbonic anhydrase Can2 and the adenylyl cyclase Cac 1. Eukaryot. Cell 5, 103-111 (2006).
32. 2 sensing during Cryptocococcus neoformans growth differentiation, and virulence. Curr. Biol. 15, 2013-2020 (2005).
33. Soto, A. R. et al. Identification and preliminary characterization of two cDNAs encoding unique carbonic anhydrases from the marine alga Emiliania huxleyi. Appl. Environ. Microbiol. 72, 5500-5511 (2006).
34. Agiilera, J. et al. Carbonic anhydrase (Nce103p): An essential biosynthetic enzyme for growth of Saccharomyces cerevisiae at atmospheric carbon dioxide pressure. Biochem. J. 391, 311-316 (2005).
35. Supuran, C. T. & Scozzafava, A. in The Carbonic Anhydrases - New Horizons (eds Chegwidden, W. R., Carter, N. D. & Edwards, Y. H.) 197-219 (Birkhauser, Basel, 2000).
36. Ilies, M. et al. Carbonic anhydrase activators. in Carbonic Anhydrase - Its Inhibitors and Activators (eds Supuran, C. T., Scozzafava, A. & Conway, J.) 317-352 (CRC, Boca Raton, 2004).
37. Briganti, F. et al. Carbonic anhydrase activators: X-ray crystallographic and spectroscopic investigations for the interaction of isozymes I and II with histamine. Biochemistry 36, 10384-10392 (1997).
38. Temperini, C. et al. Carbonic anhydrase activators. Activation of isozymes I, II, IV, VA, VII and XIV with L- and D-histidine and crystallographic analysis of their adducts with isoform II: Engineering proton transfer processes within the active site of an enzyme. Chemistry 12, 7057-7066 (2006).
39. Temperini, C. et al. Carbonic anhydrase activators. Activation of isoforms I, II, IV, VA, VII and XIV with L- and D-phenylalanine and crystallographic analysis of their aciducts with isozyme II: sterospecific recognition within the active site of an enzyme and its consequences for the drug design. J. Med. Chem. 49, 3019-3027 (2006).
40. Sun, M.-K. & Alkon, D. L. Carbonic anhydrase gating of attention: Memory therapy and enhancement. Trends Pharmacol. Sci. 23, 83-89 (2002).
41. Temperini, C. et al. Carbonic anhydrase activators: L-adrenaline plugs the active site entrance of isozyme II, activating better isoforms I, IV, VA, VII, and XIV. Bioorg. Med. Chem. Lett. 17, 628-635 (2007).
42. Splendiani, G. & Condo, S. Diuretic therapy in heart failure. G. Ital. Nefrol. 23, S74-S76 (2006).
43. +-secreting cells of mouse and rat kidney. J. Histochem. Cytochem. 51, 1217-1224 (2003).
44. Mincione, F. et al. The development of topically acting carbonic anhydrase inhibitors as anti-glaucoma agents. Curr. Top. Med. Chem. 7, 849-854 (2007).
45. Sugrue, M. F. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog. Retin. Eye Res. 19 87-112 (2000).
46. Scozzafava, A. et al. Carbonic anhydrase inhibitors. Part 74. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: Is the tail more important than the ring? J. Med. Chem. 42, 2641-2650 (1999).
47. Scozzafava, A. et al. Carbonic anhydrase inhibitors: Synthesis of water-soluble, aminoacyl/dipeptidyl sulfonamides possessing long-lasting intraocular pressure-lowering properties via the topical route. J. Med. Chem. 42, 3690-3700 (1999).
48. Ilies, M. et al. Carbonic anhydrase inhibitors: Sulfonamides incorporating furan-, thiophene- and pyrrole-carboxamido groups possess strong topical intraocular pressure lowering properties as aqueous suspensions. Bioorg. Med. Chem. 8, 2145-2155 (2000).
49. Scozzafava, A. et al. Carbonic anhydrase inhibitors: perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure-lowering agents with prolonged duration of action. J. Med. Chem. 43, 4542-4551 (2000).
50. Scozzafava, A. et al. Carbonic anhydrase inhibitors. A general approach for the preparation of water-soluble sulfonamides incorporating polyamino-polycarboxylate tails and of their metal complexes possessing long-lasting, topical intraocular pressure-lowering properties. J. Med. Chem. 45, 1466-1476 (2002).
51. Winum, J. Y. et al. Carbonic anhydrase inhibitors: N (p-sulfamoylphenyl)-α-D-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits. Bioorg. Med. Chem. Lett. 14, 225-229 (2004).
52. Cox, S. N. et al. Treatment of chronic macular edema with acetazolamide. Arch. Ophthalmol. 106, 1190-1195 (1988).
53. Gao, B. B. et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nature Med. 13, 181-188 (2007).
54. Supuran, C. T. et al. in Carbonic Anhydrase - Its Inhibitors and Activators (eds Supuran, C. T., Scozzafava, A. & Conway, J.) 67-147 (CRC, Boca Raton, 2004).
55. Maren, T. H. The development of topical carbonic anhydrase inhibitors. J. Glaucoma 4, 49-62 (1995).
56. Innocenti, X et al. Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg. Med. Chem. Lett. 15, 1149-1154 (2005).
57. Liao, S. Y. et al. Expression of cell surface transmembrane carbonic anhydrase genes CA9-and CA12 in the human eye: Overexpression of CA12 (CA XII) in glaucoma. J. Med. Genet. 40, 257-261 (2003).
58. Supuran, C. T. Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity. Expert Opin. Ther. Pat. 13, 1545-1550 (2003).
59. Casini, A. et al. Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/ sulfamides with isozymes I. II and IV. Bioorg. Med. Chem. Lett. 113, 841-845 (2003).
60. Picard, F. et al. Topiramate reduces energy and fat gains in lean (Fal?) and obese (fa/fa) Zucker rats. Obesity Res. 8, 656-663 (2000).
61. De Simone, G. et a. Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: Solution and X-ray crystallographic studies. Bioorg. Med. Chem. Lett. 15, 2315-2320 (2005).
62. Gadde, K. M. et al. Zonisamide for weight loss in obese adults: A randomized controlled trial. JAMA 289, 1820-1825 (2003).
63. Maxwell, P. H., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-275 (1999).
64. Pastorekava, S. & Pastorek. J. in Carbonic Anhydrase - Its Inhibitors and Activators (eds Supuran, C. T., Scozzafava, A. & Conway, J.) 255-281 (CRC, Boca Raton, 2004).
65. Semenza, G. L. Hypomia and cancer. Cancer Metastasis Rev. 26 223-224 (2007).
66. Brahimi-Hom, M. C. & Pouyssegur, J. Oxygen, a source of life and stress. FEBS Lett. 581, 3582-3591 (2007).
67. 2-regulated prolyl hydroxylation. Science 292, 468-472 (2001).
68. Hon, W. C. et al. Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL. Nature 417, 975-978 (2002).
69. Ratcliffe, P. J. et al. Targeting tumors through the HIF system. Nature Med. 6, 1315-1316 (2000).
70. Trastour, C. et al. HIF-1α and CA IX staining in invasive breast carcinomas: Prognosis and treatment outcome. Int. J. Cancer 120 1451-1458 (2007).
71. Pouyssegur, J. et al. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441, 437-443 (2006).
72. Ord, J. J. et al. An investigation into the prognostic significance of necrosis and hypoxia in high grade and invasive bladder cancer. J. Urol. 178, 677-682 (2007).
73. Swietach, P. et al. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev. 26, 299-310 (2007).
74. Hutchison, G. J. et al. Hypoxia-inducible factor 1-α expression as an intrinsic marker of hypoxia: Correlation with tumor oxygen, pimonidazole measurements and outcome in locally advanced carcinoma of the cervix. Clin. Cancer Res. 10, 8405-8412 (2004).
75. Sung, F. L. et al. Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in gasopharyngeal carcinoma. Cancer Lett. 253, 74-88 (2007).
76. Koukourakis, M. I. et al. Hypoxia-activated tumor pathways of angiogenesis and pH regulation independent of anemia in head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 59, 67-71 (2004).
77. Potter, C. P. & Harris, A.-L Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br. J. Cancer 89 2-7 (2003).
78. Hussain, S. A. et al. Hypoxia regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. Br. J. Cancer 96, 104-109 (2007).
79. Swinson, D. E. et al. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J. Clin. Oncol. 21, 473-482 (2003).
80. Dorai, T. et al. Role of carbonic anhydrases in the progression of renal cell carcinoma subtypes: Proposal of a unified hypothesis. Cancer Invest. 24, 754-779 (2006).
81. Abbate, F. et al. Carbonic anhydrase inhibitors: X ray crystallographic structure of the adduct of human isozyme II with a EMATE, a dual inhibitor of carbonic anhydrases and steroid sulfatase. Bioorg. Med. Chem. Lett. 14, 231-234 (2004).
82. Di Fiore, A. et al. Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related, cyclooxygenase II "selective" inhibitor celecoxib. Bioorg. Med. Chem. Lett. 16, 437-442 (2006).
83. Abbate, F. et al. Carbonic anhydrase inhibitors: X ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride. Bioorg. Med. Chem. Lett. 14, 337-341 (2004).
84. Svastova, E. et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 577, 439-445 (2004).
85. Cecchi, A. et al. Carbonic anhydrase inhibitors. Sulfonamides inhibit isozyme IX mediated acidification of hypoxic tumors. Fluorescent sulfonamides design as probes of membrane-bound carbonic anhydrase isozymes involvement in tumorigenesis. J. Med. Chem. 48, 4834-4841 (2005).
86. Menchise, V. et al. Carbonic anhydrase inhibitors: Stacking with Phe 131 determines active site binding region of inhibitors as exemplified by the X-ray crystal structure of a membrane-impermeant antitumor sulfonamide complexed with isozyme II. J. Med. Chem. 48, 5721-5727 (2005).
87. Ilies, M. A., et al. Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives. J. Med. Chem. 46 2187-2196 (2003).
88. Winum, J. Y. et al. Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors. J. Med. Chem. 46, 2197-2204 (2003).
89. Winum, J. Y. et al. Carbonic anhydrase inhibitors: Inhibition of transmembrane, tumor-associated isozyme IX, and cytosolic isozymes I and II with aliphatic sulfamates. J. Med. Chem. 46, 5471-5477 (2003).
90. Pastorekova, S. et al. Carbonic anhydrase inhibitors: The first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX Bioorg. Med. Chem. Lett. 14, 869-873 (2004).
91. Vullo, D. et al. Carbonic anhydrase inhibitors: Inhibition of the tumor-associated isozyme IX with fluorine-containing sulfonamides. The first subnanomolar CA IX inhibitor discovered. Bioorg. Med. Chem. Lett. 14, 2351-2356 (2004).
92. Casey, J. R. et al. Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX. J. Med. Chem. 47, 2337-2347 (2004).
93. Supuran, C. T. et al. COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents. Mini Rev. Med. Chem. 4 625-632 (2004).
94. Garaj, V. et al. Carbonic anhydrase inhibitors: Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties. Bioorg. Med. Chem. Lett. 14, 5427-5433 (2004).
95. Innocenti, A. et al. Carbonic anhydrase inhibitors: The first on-resin screening of a 4-sulfamoylphenylthiourea library. J. Med. Chem. 47, 5224-5229 (2004).
96. Cecchi, A. et al. Carbonic anhydrase inhibitors: Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfanamides derived from 4-isothiocyanato-benzolamide. Bioorg. Med. Chem. Lett. 14, 5775-5780 (2004).
97. Winum, J. Y. et al. Carbonic anhydrase inhibitors: Synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfanamides incorporating hydrazino moieties. J. Med. Chem. 48, 2121-2125 (2005).
98. Winum, J. Y. et al. Carbonic anhydrase inhibitors: Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg. Med. Chem. Lett. 15, 579-584 (2005).
99. Winum, J. Y. et al. Carbonic anhydrase inhibitors: Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with N-hydroxysulfamides - a new zinc-binding function in the design of inhibitors. Bioorg. Med. Chem. Lett. 15, 2353-2358 (2005).
100. Winum, J. Y. et al. Carbonic anhydrase inhibitors. Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II. and IX with boron-containing sulfanamides, sulfamides, and sulfamates: Toward agents for boron neutron capture therapy of hypoxic tumors. Bioorg. Med. Chem. Lett. 15, 3302-3306 (2005).
101. Thiry, A. et al. Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J. Med. Chem. 49, 2743-2749 (2006).
102. Wilkinson, B. L. et al. A novel class of carbonic anhydrase inhibitors: Glycoconjugate benzene sulfonamides prepared by "click-tailing". J. Med. Chem. 49, 6539-6548 (2006).
103. Wilkinson, B, L. et al. Carbonic anhydrase inhibitors: Inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides. J. Med. Chem. 50, 1651-1657 (2007).
104. Dubois, L. et al. Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiother. Oncol. 83, 367-373 (2007).
105. Abbate, F. et al. Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg. Med. Chem. Lett. 14, 217-223 (2004).
106. Owa, T. et al. Array-based structure and gene expression relationship study of antitumor sulfonamides including N-[2-[(4-hydroxyphenyl)-amino]-3-pyridinyl]-4-methoxy- benzenesulfonamide and N-(3-chloro-7-indolyl)-1, 4-benzenedisulfonamide. J. Med. Chem. 45, 4913-4922 (2002).
107. Owa, T. et al. Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. J. Med. Chem. 42, 3789-3799 (1999).
108. Talbot, D. C. et al. A randomized phase II pharmacokinetic and pharmacodynamic studly of indisulam as second-line therapy in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 13 1816-1822 (2007).
109. Riihonen, R. et al. Membrane-bound carbonic anhydrases in osteoclasts. Bone 40, 1021-1031 (2007).
110. Innocenti, A. et al. Carbonic anhydrase inhibitors. Inhibition of the β-class enzyme from the methanoarchaeon Methanobacterium thermoautotrophicum (Cab) with anions. Bioorg. Med. Chem. Lett. 14, 4563-4567 (2004).
111. Zimmerman, S. A. et al. Carbonic anhydrase inhibitors. Inhibition of the prokariotic β and γ-class enzymes from Archaea with sulfonamides. Bioorg. Med. Chem. Lett. 14, 6001-6006 (2004).
112. Zimmerman, S. A., Ferry, J. G. & Supuran C. T. Inhibition of the archaeal β-Class (Cab) and γ-Class (Cam) carbonic anhydrases. Curr. Top. Med. Chem. 7, 901-908 (2007).
113. Sun, M. K. & Alkon, D. L. Pharmacological enhancement of synaptic efficacy, spatial learning, and memory through carbonic anhydrase activation in rats. J. Pharmacol. Exp. Ther. 297, 961-967 (2001).
114. Supuran, C. T. & Clare, B. W. Carbonic anhydrase activators. Part 3. Structure-activity correlations for a series of isozyme II activators. J. Pharm. Sci. 83, 768-773 (1994).
115. Supuran, C. T. & Scozzafava, A. Carbonic anhydrase activators: Amino acyl/dipeptidyl histamine derivatives bind with high affinity to isozymes I, II and IV and act as efficient activators. Bioorg. Med. Chem. 7, 2915-2923 (1999).
116. Scozzafava, A. & Supuran, C. T. Carbonic anhydrase activators: High affinity isozymes I, II, and IV activators, incorporating a beta-alanyl-histidine scafold. J. Med. Chem. 45, 284-291 (2002).
117. Ilies, M. et al. Carbonic anhydrase activators: Design of high affinity isozymes I, II, and IV activators, incorporating tri-/ tetrasubstituted-pyridinium-azole moieties. J. Med. Chem. 45 504-510 (2002).
118. Scozzafava, A. & Supuran, C. T. Carbonic anhydrase activators: Human isozyme II is strongly activated by oligopeptides incorporating the carboxyterminal sequence of the bicarbonate anion exchanger AE1. Bioorg. Med. Chem. Lett. 12, 1177-1180 (2002).
119. Parkkila, S. et al. Carbonic anhydrase activators: Activation of isozyme XIII with amino acids and amines. Bioorg. Med. Chem. Lett. 16, 3955-3959 (2006).
120. Temperini, C. et al. Carbonic anhydrase activators: The first X-ray crystallographic study of an adduct of isoform I. Bioorg. Med. Chem. Lett. 16, 5152-5156 (2006).
121. Nishimori, I. et al. Carbonic anhydrase activators: The first activation study of the human secretory isoform VI with amino acids and amines. Bioorg. Med. Chem. Lett. 17, 5351-5357 (2007).